further proof that these downward manipulations come from the...

further proof that these downward manipulations come from the USA is Pilcher's strategic TH implemented in the right time to defuse this boycott of the price per share as much as possible. it was decided to stop the market a couple of sessions before the Pitt announcement which was communicated with the Americans on holiday. as soon as they returned fully operational, they re-established the price from where it started before the announcement, effectively canceling all the added capitalization. $21 is a benchmark for defining Neuren's overall price. Pilcher does not yet have the support of large institutions to counter these boycotts, with the aim of downgrading the price per share by virtue of a not too generous offer for a change of control. Pilcher tries to capitalize on the stock, but in fact there are no shares available on the market in significant quantities to enable the entry of large capital. everything will depend on the next few days, when Pilcher will try to convince big American finance. Jefferies was hired by Neuren to make a realistic and consistent estimate of the entire Neuren reality. Pilcher will have room to negotiate on this estimate, but I presume downwards, precisely due to the weakness of the support he has from the institutional players present in the stock. I hope that Pilcher's fragile emotional state and evident tiredness in these hours do not affect the negotiations in America. inevitably the good Jon will have to deal with those in charge in the next few hours. we have arrived at a sort of reckoning. in the meantime Neuren has recently updated the European patents including the one on PW, which leaves much doubt as to the true interest for which it was even financed with the latest ADC and who knows for which client. despite the decision to stop it, useful information still came from the trial given that it remained active for the first 4 weeks of evaluation and the following 6 weeks of experimentation. I remember that this trial was started with the first patient at the end of June 2023. after two days the announcement of the end of PMD enrollment arrived and after exactly two weeks the agreement with Acadia for 2591 Rett/FX and the ROW sale . at that precise moment, therefore between the end of June and mid-July 2023, something very important was decided, taking note of the density of key news and its relative concentration in a very short period. given that nothing is random, we can reasonably hypothesize that exactly one year after these events, what was decided in great secrecy at the time will materialize.